Model-informed drug development for immune checkpoint inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 734-742, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-876527
ABSTRACT
With a deepening understanding of cancer treatment, immune checkpoint inhibitors are recognized widely as a novel fundamental remedy for various malignancies with effectiveness and safety. With the development of pharmacometrics, model-informed drug development (MIDD) has emerged to accelerate the process of clinical research for new drugs and improve the accuracy of decision-making in new drug research, especially for immune checkpoint inhibitors. As a typical illustration, the research development of pembrolizumab is presented in this review to highlight the application of MIDD, which may provide a reference for the development of other new antitumor drugs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS